Literature DB >> 2156886

Brain natriuretic peptide administered to man: actions and metabolism.

A McGregor1, M Richards, E Espiner, T Yandle, H Ikram.   

Abstract

To investigate the effects and metabolism of brain natriuretic peptide (BNP) in man, eight normal subjects received 3-h infusions of synthetic porcine BNP (2 pmol/kg.min) in a placebo-controlled study. The MCR and plasma half-life of BNP were 2.69 L/min and 3.1 min, respectively. BNP clearly suppressed PRA to less than 50% of placebo values (P less than 0.001). Plasma aldosterone concentrations were also significantly reduced by 30% (P less than 0.05). Urinary sodium excretion tended to rise (P = 0.054), and urinary cGMP excretion was clearly enhanced (P less than 0.01). Systemic and renal hemodynamics, hematocrit, plasma protein concentrations, plasma ACTH, arginine vasopressin, PRL, and catecholamines were unchanged. Porcine BNP has a similar range of effects and is similarly metabolized in man as human ANP. Further elucidation of the possible role of BNP as a circulating hormone in man awaits measurement of tissue and plasma concentrations of human BNP in health and disease and provision of fuller dose-response data for human as well as porcine BNP.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156886     DOI: 10.1210/jcem-70-4-1103

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  Conservation of the kinaselike regulatory domain is essential for activation of the natriuretic peptide receptor guanylyl cyclases.

Authors:  K J Koller; F J de Sauvage; D G Lowe; D V Goeddel
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

Review 2.  Nesiritide for acute decompensated heart failure: does the benefit justify the risk?

Authors:  Jonathan Sackner-Bernstein; Keith D Aaronson
Journal:  Curr Cardiol Rep       Date:  2007-05       Impact factor: 2.931

3.  Brain natriuretic peptide predicts mortality in the elderly.

Authors:  T Wallén; S Landahl; T Hedner; K Nakao; Y Saito
Journal:  Heart       Date:  1997-03       Impact factor: 5.994

4.  AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure.

Authors:  Wei Wang; Ying Ou; Yanggu Shi
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

5.  Perioperative changes in plasma brain natriuretic peptide concentrations in patients undergoing cardiac surgery.

Authors:  K Morimoto; T Mori; S Ishiguro; N Matsuda; Y Hara; H Kuroda
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

6.  Brain natriuretic peptide and fluid volume homeostasis--studies during cardiopulmonary bypass surgery.

Authors:  A Ationu; M Burch; M Elliott; N Carter
Journal:  Clin Auton Res       Date:  1993-08       Impact factor: 4.435

Review 7.  Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics.

Authors:  A C Tan; F G Russel; T Thien; T J Benraad
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

Review 8.  Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications.

Authors:  Lincoln R Potter; Andrea R Yoder; Darcy R Flora; Laura K Antos; Deborah M Dickey
Journal:  Handb Exp Pharmacol       Date:  2009

Review 9.  Intravenous vasodilator therapy in congestive heart failure.

Authors:  Kourosh Moazemi; Jatinder S Chana; Anna Marie Willard; Abraham G Kocheril
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 10.  Cardiac natriuretic peptides.

Authors:  Jens P Goetze; Benoit G Bruneau; Hugo R Ramos; Tsuneo Ogawa; Mercedes Kuroski de Bold; Adolfo J de Bold
Journal:  Nat Rev Cardiol       Date:  2020-05-22       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.